Multiple vial sizes to match different protocol needs
Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, et al
Preliminary results from the SURPASS-J-mono study in Japanese patients with T2D who were either therapy nave or on an antidiabetic monotherapy showed a head-to-head comparison of a tirzepatide treatment compared to therapy with the GLP-1RA dulaglutide at a dose of 0.75 mg (76)
One of the most common and debilitating complications seen in Long COVID, ME/CFS, and dysautonomia is Small Fiber Neuropathy (SFN)
Aquilani RSPF-I, Paolo Iadarola P, Fau - Barbieri, Annalisa Barbieri A, Fau - Boschi F, Boschi F
A report from Trilliant Health in 2023 found that prescriptions for GLP-1 drugs increased by 300 percent from 2018